Mp49-06 Prostate Specific Antigen Screening Amongst Smokers: A U.S. National Behavioral Analysis

You have accessJournal of UrologyProstate Cancer: Detection 39-40%]. The prevalence of PSA screening was 42% 95% CI; 41-44% for never smokers, 27% 95% CI; 25-29% for current smokers, and 42% 95% CI; 39-40% for former smokers (Table 1). Among current smokers, PSA screening prevalence was 27% 95% CI; 24-29% daily smokers and 29% 95% CI; 24-33% for non-daily smokers. The adjusted relative risk for undergoing PSA screening in comparison to never smokers was 0.81 for current smokers (95% CI: 0.75-0.88, p<0.01) and 0.99 for former smokers (95% CI: 0.94-1.03, p=0.53) (Table 2). CONCLUSIONS: Smokers are significantly less likely to undergo PSA screening. Resultant delays in diagnosis may contribute to worse PCa detection and outcomes in smokers. Interventions to increase screening in this population may be particularly effective in improving PCa outcomes. Further studies are needed to develop strategies to address reduced PSA screening rates in smokers. Source of Funding: N/A © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e784 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Ian Mitchell Harmatz More articles by this author Khalid Y. Alkhatib More articles by this author Morgan Leff More articles by this author Brian D. Cortese More articles by this author Nathaniel McLaughlan More articles by this author Daniel S. Roberson More articles by this author Katharine F. Michel More articles by this author Benjamin Schurhamer More articles by this author Daniel J. Lee More articles by this author Stanley Bruce Malkowicz More articles by this author Trinity J. Bivalacqua More articles by this author Thomas Guzzo More articles by this author Phillip M. Pierorazio More articles by this author Expand All Advertisement PDF downloadLoading ...